Back

The predictive value of impedance for defibrillation success after subcutaneous implantable cardioverter-defibrillator implantation: a reliable indicator?

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Extravascular implantable cardioverter-defibrillator therapy Implantable Cardioverter-Defibrillator (ICD) EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Ms Jolien Anne De Veld

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Longevity of contemporary subcutaneous implantable cardioverter-defibrillators: multicenter real-world data
Doctor M. Ziacchi (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Subcutaneous ICD therapy across underlying cardiac diseases in paediatric and young adult patients: insights from the european SIDECAR registry
Doctor M. Silvetti (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Durability and coil positioning in paediatric epicardial ICD systems: insights from a 20-year retrospective study
Doctor S. Kwok (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Two-versus three-incision techniques for subcutaneous implantable cardioverter-defibrillator implantation: insights from the HONEST registry
Doctor L. Donisi (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Six-month safety and therapy efficacy of the extravascular implantable defibrillator in those 65 years or older: real-world results from the enlighten study post approval registry
Professor D. Duncker (Hannover, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Extravascular implantable cardioverter-defibrillator therapy

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Presentation
Real-world evaluation of the PRAETORIAN score in subcutaneous ICD recipients: a multicenter registry
thumbnail
Congress Presentation
Can we predict if defibrillation testing of a subcutaneous implantable cardioverter defibrillator can be avoided safely at device replacement?
thumbnail
Congress Presentation
Defibrillation threshold testing in hypertrophic cardiomyopathy: acute outcomes and long-term follow-up

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources